With the introduction of vaccines in the past few centuries, there has been a reduction or eradication of major infectious diseases that had long affected human health. Nevertheless, there are still a number of infectious diseases that plague communities around the globe.

At Clover, we believe that we have the responsibility as an innovative biopharma company to fully leverage our technological advantages and develop safe and effective vaccines for communities around the globe.

We are using our proprietary Trimer-Tag© technology to develop the S-Trimer COVID-19 vaccine candidates as well as vaccines for rabies, influenza, respiratory syncytial virus (RSV) and human immunodeficiency virus (HIV).

These enveloped RNA viruses all have trimeric envelope spike glycoproteins which are used to infect us, which makes Trimer-Tag© an ideal technology for the production of vaccines against these viruses.

SARS-CoV-2 (the virus that causes COVID-19) is an RNA virus that has a trimeric spike (S) protein on its viral envelope that is responsible for binding to the host cell surface receptor, ACE2, and subsequent viral entry, making it the primary target antigen for vaccine development. Constructed by Clover’s proprietary Trimer-Tag© technology as a trimeric SARS-CoV-2 S-protein subunit vaccine candidate, the S-Trimer COVID-19 vaccine resembles the native trimeric viral spike protein and is produced via a rapid mammalian cell-culture based expression system.